Carisma Therapeutics (CARM) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; expects to report Regimen Level 2 data in second quarter of 2024 First Quarter 2024 Highlights and Upcoming Milestones · CT-0508 (Anti-HER2 CAR-Macrophage) o In late March 2024, Carisma made the decision to pause further development of CT-1119, pending additional financing. o O ...